login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ASTRAZENECA PLC-SPONS ADR (AZN) Stock News
USA
- NASDAQ:AZN -
US0463531089
-
ADR
82.23
USD
-0.38 (-0.46%)
Last: 10/29/2025, 8:14:17 PM
82.24
USD
+0.01 (+0.01%)
Pre-Market:
10/30/2025, 4:47:09 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AZN Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Chartmill
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
7 days ago - By: Zacks Investment Research
- Mentions:
PFE
NVO
LLY
VKTX
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
7 days ago - By: Benzinga
- Mentions:
LLY
NVO
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
8 days ago - By: Benzinga
Peering Into AstraZeneca PLC's Recent Short Interest
10 days ago - By: Zacks Investment Research
- Mentions:
AMAT
LH
RSG
EME
...
Top Research Reports for AstraZeneca, RTX & Applied Materials
10 days ago - By: Zacks Investment Research
- Mentions:
PFE
MRK
ABBV
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
10 days ago - By: Zacks Investment Research
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
10 days ago - By: Stocktwits
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
11 days ago - By: AstraZeneca
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
12 days ago - By: AstraZeneca
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
12 days ago - By: Investor's Business Daily
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
12 days ago - By: AstraZeneca
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
12 days ago - By: Zacks Investment Research
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
13 days ago - By: AstraZeneca
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
13 days ago - By: Zacks Investment Research
- Mentions:
SNY
MRK
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
13 days ago - By: Zacks Investment Research
- Mentions:
JNJ
PFE
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
13 days ago - By: AstraZeneca
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
13 days ago - By: AstraZeneca
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
14 days ago - By: The Motley Fool
- Mentions:
LLY
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
15 days ago - By: Stocktwits
- Mentions:
DFAX
QQMG
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
15 days ago - By: AstraZeneca
AstraZeneca unveils expanded manufacturing facility in Texas
17 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
ABBV
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
17 days ago - By: Zacks Investment Research
- Mentions:
HSBC
RIO
SHEL
US-China Trade Tension Escalates: Should You Seek Refuge in UK ETFs?
17 days ago - By: AstraZeneca
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
17 days ago - By: Zacks Investment Research
- Mentions:
QCOM
APLD
LEVI
Company News for Oct 13, 2025
20 days ago - By: Stocktwits
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump
20 days ago - By: Zacks Investment Research
- Mentions:
BMY
MRK
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
21 days ago - By: Stocktwits
- Mentions:
DFAX
QQMG
AstraZeneca Announces $4.5B Investment In Virginia
Please enable JavaScript to continue using this application.